Ref. Ares(2015)5300450 - 23/11/2015
Please find below some information on the activities of the EURIPID Collaboration.
Please note that the actual website of the Collaboration is not publicly accessible but we are happy to provide you with some key information on our work and partnership. The undertaking receives some co-funding from European Commission, as outlined.
Grant Name: Statistical data for medicinal product pricing
Start Date: 2015-08-01
End Date: 2018-07-31
Max. EU Contribution: EUR 299,999.70
The consortium acting on behalf of the EURIPID Collaboration under this grant consists of:
EURIPID Collaboration is a voluntary and strictly non-profit cooperation between mostly European countries on building up and maintaining a database with information on national prices of medicinal products in a standardized format.
EURIPID database is currently exclusively available online for national competent authorities for pricing and reimbursement of medicinal products, who agreed on the rules of the collaboration and who participate actively.
EURIPID database contains data on official prices of publicly reimbursed, mainly out-patient medicinal products that are published by national authorities in line with the Transparency Directive 89\105\EC.
24+ European Countries participating
10 000 000+ Price References of medicinal products
24h online availability of database
8+ Years of Experience of project partners
2009 First financial contribution by EU
|Besides regular maintenance tasks, activities under the Grant will identify and implement extra information allowing authorities to obtain price information in a more efficient way and lower the risk of making decisions based on incorrect or incomplete data. EURIPID database has been of great value to the authorities in the past years aiding them in their decision making duties. With the expanded funding opportunity from the EC, the EURIPID consortium will be able to achieve even more additional value for users.||The EURIPID collaboration will share experience and - with the consideration of all relevant stakeholders opinions - will develop a technical Guidance Document on a coordinated approach regarding External Reference Pricing. This document will be available to the general public and thus will help to avoid or mitigate potential negative impact for patient access to medicines because of unskilled use of external reference pricing policy.|
Stakeholders at EU level that will be involved in process are
The content of this website represents the view of the EURIPID consortium members only and is their sole responsibility. It can not be considered to reflect the views of the European Commission and/or the Consumer Health Agriculture and Food Executive Agency (CHAFEA) or any other body established within the remit of the Institutions of the European Union. The European Commission and the CHAFEA do not accept any responsibility for use that may be made of the information it contains.